A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects With Low HDL-C Levels.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2013
At a glance
- Drugs JTT 302 (Primary)
- Indications Low HDL cholesterol
- Focus Therapeutic Use
- Sponsors Akros Pharma
- 26 Sep 2008 New trial record.